Pharmacological targeting of the FGFR-KLB system dramatically improves metabolic disturbances in rodent models of obesity, T2D, and NAFLD, observations that paved the way for more advanced drug development. This evidence concerns the gene KLB and metabolic dysfunction-associated steatotic liver disease.